Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Abstract:
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on June 14, 2019, the Compensation Committee of the Board of Directors approved "inducement" grants to 11 new employees under Rule 5635(c)(4) of the NASDAQ Marketplace Rules.

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)

Pasadena. CA | Posted on June 22nd, 2019

The option grants entitle the employees, in aggregate, to purchase up to 70,000 shares of common stock. The strike price of the options is set at an exercise price per share of $25.82, the last reported closing price of the Company's common stock on June 14, 2019, the date of grant, except for certain shares which will be priced at the last reported closing price of the Company’s common stock on the date of hire of four new employees, anticipated to be within 3 months of the date of the approval. The grants are outside of the Company's stockholder-approved equity incentive plans. The options vest and become exercisable over a period of four years.

####

About Arrowhead Pharmaceuticals, Inc.
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts .

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

For more information, please click here

Contacts:
Arrowhead Pharmaceuticals, Inc.
Vince Anzalone, CFA
626-304-3400


Investors and Media:
LifeSci Advisors, LLC
Brian Ritchie
212-915-2578

www.lifesciadvisors.com

Copyright © Arrowhead Pharmaceuticals, Inc.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Nano bulb lights novel path: Rice University engineers create tunable, nanoscale, incandescent light source September 20th, 2019

The future of materials with graphene nanotubes starts in Japan September 19th, 2019

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

Investments/IPO's/Splits

Picosun accelerates growth with a notable Finnish investment June 28th, 2019

Nanometrics and Rudolph Technologies to Jointly Participate in the 11th Annual CEO Investor Summit 2019 June 27th, 2019

Nanometrics and Rudolph Announce Merger Agreement to Create a Premier Semiconductor Process Control Company June 24th, 2019

180 Degree Capital Corp.’s Portfolio Company, TheStreet, Inc., Enters into Agreement to be Acquired by TheMaven, Inc. for $16.5 Million June 13th, 2019

Nanomedicine

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

Inspired by natural signals in living cells, researchers design artificial gas detector: Tiny box puts itself together and glows September 13th, 2019

New health monitors are flexible, transparent and graphene enabled September 13th, 2019

Announcements

Nano bulb lights novel path: Rice University engineers create tunable, nanoscale, incandescent light source September 20th, 2019

The future of materials with graphene nanotubes starts in Japan September 19th, 2019

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

Nanobiotechnology

Tiny bubbles in our body could fight cancer better than chemo September 18th, 2019

Keystone Nano Announces FDA Approval of Investigational New Drug Application for Ceraxa for the Treatment of Acute Myeloid Leukemia September 18th, 2019

Scientists create a nanomaterial that is both twisted and untwisted at the same time: The material developed at University of Bath allows for incredibly sensitive detection of the direction molecules twist September 13th, 2019

Inspired by natural signals in living cells, researchers design artificial gas detector: Tiny box puts itself together and glows September 13th, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project